Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 77Prostatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 50Breast Neoplasms 49Esophageal Neoplasms 47Rectal Neoplasms 41Lung Neoplasms 40Squamous Cell Carcinoma of Head and Neck 32Gliosarcoma 31Head and Neck Neoplasms 30Brain Neoplasms 30Pancreatic Neoplasms 29Uterine Cervical Neoplasms 27Neoplasm Metastasis 23Glioma 23Neoplasms 22Oropharyngeal Neoplasms 20Esophageal Squamous Cell Carcinoma 20Sarcoma 19Melanoma 18Astrocytoma 17Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11Burkitt Lymphoma 10

Interventions

Radiotherapy 2Taxes 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hemoptysis × Radiation × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡